Pfizer announced a wide-ranging oncology collaboration with Innovent Biologics covering 12 early-stage and de novo antibody-drug conjugate and multispecific programs. The deal includes $650 million upfront and up to $9.85 billion in milestones, with royalties, as Innovent takes discovery and early development responsibilities through Phase 1. Under the agreement structure, Pfizer assumes global development for certain programs after early studies, while ownership and co-development cost-sharing vary across the portfolio. The partnership continues a pattern of large pharma sourcing early candidates from China’s rapid clinical build-out, particularly in ADCs and multispecific antibodies. For the biotech sector, the package adds incremental competitive pressure to other next-generation targeted oncology platforms and highlights how funding and development risk is being distributed across discovery-stage partners and global developers.